Document is current
Any future updates will be listed below
-
Authors
Citrome, Leslie
Sánchez del Rio, Margarita
Dong, Yan
Nichols, Russell M.
Tockhorn-Heidenreich, Antje
Foster, Shonda A.
Stauffer, Virginia L.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02614183 at ClinicalTrials.govnct02614196 at ClinicalTrials.govDocuments that mention this clinical trial
Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis
https://doi.org/10.1007/s12325-021-01708-8
Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm
https://doi.org/10.1007/s12325-021-01848-x
nct02614261 at ClinicalTrials.govDocuments that mention this clinical trial
Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis
https://doi.org/10.1007/s12325-021-01708-8
Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm
https://doi.org/10.1007/s12325-021-01848-x
nct03559257 at ClinicalTrials.govDocuments that mention this clinical trial
Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis
https://doi.org/10.1007/s12325-021-01708-8
Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm
https://doi.org/10.1007/s12325-021-01848-x
Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)
https://doi.org/10.1007/s11136-020-02623-1
Documents that mention this clinical trial
Effect of Galcanezumab on Total Pain Burden in Patients Who Had Previously Not Benefited from Migraine Preventive Medication (CONQUER Trial): A Post Hoc Analysis
https://doi.org/10.1007/s12325-022-02233-y
Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm
https://doi.org/10.1007/s12325-021-01848-x
Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial
https://doi.org/10.1007/s12325-021-01911-7
Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)
https://doi.org/10.1007/s40261-021-01115-5
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 30 April 2021
Accepted: 25 June 2021
First Online: 15 July 2021
